stockrow
Friday 6 November 2026
Export RDHL’s income statement to Excel — free account
Redhill Biopharma Ltd.
RDHL Healthcare Drug Manufacturers Specialty & Generic
Redhill Biopharma Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $286,000.00, down 96.4% from fiscal 2024.
0.43
0.00
0.00%
Follow RDHL
Alert me
| Older periods | Jun '23 | Jun '24 | Jun '25 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | — | — | — |
P/S ratio |
19.31 | — | — | — | |
P/FCF ratio |
0.00 | — | — | — | |
P/Operating CF |
(33.20) | — | — | — | |
P/B ratio |
170.01 | — | — | — | |
Price to Tangible BV |
0.00 | — | — | — | |
EV/Sales |
18.86 | — | — | — | |
EV/EBITDA |
0.00 | — | — | — | |
EV/Operating CF |
(17.28) | — | — | — | |
EV/FCF |
(6.63) | — | — | — | |
Quick Ratio |
0.68 | 0.42 | 0.38 | 0.20 | |
Current Ratio |
0.96 | 0.74 | 0.56 | 0.34 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.30 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(23.62) | 0.00 | 0.00 | — | |
Capex/Depreciation |
0.00 | 0.00 | (0.02) | — | |
Interest Coverage |
0.00 | — | — | — | |
Research and Development Expense of Revenue |
69.44% | — | — | — | |
Selling, General and Administrative Expense of Revenue |
386.15% | — | — | — | |
Intangible Assets out of Total Assets |
0.16 | 0.25 | 0.30 | 0.20 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | — | |
Graham Net Nets |
(0.01) | — | — | — | |
Graham Number |
0.00 | — | — | — | |
Earnings Yield |
(2,035.56%) | — | — | — | |
Free Cash Flow Yield |
(14.73%) | — | — | — | |
Revenue per Share |
0.09 | — | — | — | |
Operating CF per Share |
(0.90) | 0.00 | 0.00 | — | |
Capex per Share |
0.00 | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | — | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | — | — | — | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(0.01) | (6.19) | (5.02) | — | |
Working Capital |
(1.14) | (5.53) | (9.73) | (16.99) | |
Capital Expenditures |
(0.01) | 0.00 | 0.00 | — | |
Net Current Asset Value |
(4.52) | (6.26) | (10.23) | (18.78) | |
EV/EBIT |
0.00 | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — | |
Price to Operating Income |
0.00 | — | — | — | |
| Other line items | |||||
Average Receivables |
18.33 | 18.49 | 19.94 | — | |
Average Payables |
3.74 | 3.35 | 2.53 | 2.48 | |
Average Inventory |
8.33 | 8.19 | 7.09 | — | |
Average Assets |
101.50 | 89.61 | 88.62 | 42.55 | |
Average Common Equity |
(4.23) | (22.98) | (26.41) | 0.46 |
Columns are period end dates · fundamentals updated 26 Oct 2026